| INTRODUC TI ON
Neuraminidase inhibitors (NAIs) reduce the duration and severity of illness caused by influenza in both adults and children, although the effects may be modest because NAIs inhibit viral replication by interfering with the release of virus from infected cells, but are not virucidal. [1] [2] [3] NAIs are effective when administered within 48 hours of the onset of influenza symptoms 2 and can reduce the rate of secondary infection when used prophylactically by asymptomatic people who are in close contact with an infected person (eg, household members). 1, 3, 4 In Japan, unlike in most other countries, NAIs are mainly prescribed for outpatients. 5 The Japanese health insurance system covers the cost of rapid influenza diagnostic tests (RIDTs), and more than 80% of Japanese patients with influenza visit a medical clinic within 48 hours of onset, greatly facilitating the early diagnosis and treatment of influenza. 5 NAIs currently approved in Japan for the treatment of influenza include oral oseltamivir, inhaled zanamivir, inhaled laninamivir, and intravenous peramivir.
Reduction in the household transmission of influenza is critical in reducing the overall public health effects of this infectious disease. Several studies suggest that NAI treatment of the primary (index) infected patient may reduce household transmission of influenza without the need for prophylaxis of uninfected individuals. [6] [7] [8] [9] [10] [11] [12] [13] Effective reduction in transmission by treatment of the index patient would avoid the logistic and cost implications of widespread prophylactic use of NAIs. Influenza transmission is related to the extent and duration of virus shedding, which varies between influenza subtypes 14 and may be reduced by NAI treatment. 7, 11, 15 We recently conducted a randomized controlled trial examining the effect of NAIs on virus clearance in children aged 4-12 years with influenza A infection. 16 The time required for clearance of influenza virus was significantly shorter in children treated with peramivir than in those treated with oseltamivir (median time to clearance 2.05 vs 3.08 days, adjusted P = 0.0348).
Differences in the ability of NAIs to reduce viral shedding or accelerate viral clearance may translate into different effectiveness in reducing transmission. Previous studies comparing the ability of different NAIs to reduce household transmission have led to varying results. 6, [8] [9] [10] However, these studies have been limited by small sample size, number of NAIs used, and/or retrospective design (eg, claims database). Further, none of the studies separately analyzed transmission of both influenza A (including subtypes) and influenza B, nor did any include the more recently available NAI, peramivir.
The primary objective of this prospective, observational, household transmission study was to compare the daily secondary infection rate (SIR) in households of index patients treated with one of four NAIs available in Japan (oseltamivir, zanamivir, laninamivir, and peramivir). Secondary objectives included the effect of different NAIs on the rate of household members with secondary infection and the proportion of households with at least one secondary infection. (Osaka, Japan).
| MATERIAL S AND ME THODS

| Study design
| Study population
Patients of any age who attended the Hirotsu Clinic and were 
| Data collection
The following information was collected, from medical records held at Hirotsu Clinic (or, in a few cases, from other clinics), pa- 
| Outcome measures
The primary outcome was the daily SIR, defined as the probability of passing influenza virus to an uninfected household member per day. Secondary outcomes included the rate of household members with secondary infection, defined as the number of infected household members divided by the total number of uninfected household members at baseline (ie, onset time of influenza symptoms in the index patient), and the proportion of households with secondary infection patients, defined as the number of households with at least one secondary infection divided by the total number of households with any uninfected household members at baseline.
| Statistical analysis
The analysis population included index patients and secondary infection patients within households. Patients who had infection in multiple seasons were considered as different patients. Summary (Table S1 ). The proportion of households with secondary infection patients was compared among the four NAIs using a logistic regression model. Sensitivity analyses were performed using the same methods as for the primary analysis.
For all analyses, a two-sided test with statistical significance level of 0.05 was used. There was no imputation for missing data, no adjustment
F I G U R E 2 Daily household secondary infection rates for influenza A (panel A), A/H1pdm (panel B), A/H3 (panel C), and B (panel D).
Shown are unadjusted estimates and 95% confidence intervals (CI) when patients (index and secondary infection) were treated with peramivir, oseltamivir, zanamivir, or laninamivir, or when patients were untreated, and unadjusted and adjusted odds ratios (OR) of pairwise comparisons between neuraminidase inhibitors for multiplicity due to the exploratory nature of the analysis, and no outliers were excluded. All statistical analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, NC, USA).
| RE SULTS
| Demographic characteristics of index patients
A total of 1807 index patients were identified, most of whom had influenza A infections (Table 1; Table S2 ). Although most index patients were relatively young, the range of ages was broad in all study
groups. Approximately 16% of index patients reported having had influenza during the previous season. Approximately 50% of index patients reported having influenza vaccination in the previous season, and a similar percentage reported vaccination in the current season.
Most index patients started NAI treatment within 2 days of disease onset, with the mean and median <1 day for most study groups.
Peramivir and oseltamivir were the most commonly prescribed NAIs for influenza A, and zanamivir was the most commonly prescribed NAI for influenza B. Laninamivir was the least commonly used NAI, and a small number of patients were untreated. There were approximately 3 (mean) uninfected people per household at the onset of the primary infection. Approximately 3400 patients (both index and secondary patients) from 1200 families were included in the analysis.
| Daily secondary infection rate
The daily SIR differed according to the NAI used by index and secondary infection patients ( Figure 2 ). Daily SIRs for all influenza subtypes were highest for patients treated with oseltamivir compared with other NAIs. Pairwise comparisons of the daily SIR indicated that household transmission of influenza A was lower with peramivir or zanamivir than with oseltamivir ( Figure 2A) . This difference was primarily due to differences in reducing transmission of subtype A/H3; although after adjusting for covariates, statistical significance was reached only for the zanamivir vs oseltamivir comparison ( Figure 2C ). Transmission of influenza B was also lower with zanamivir or laninamivir than with oseltamivir ( Figure 2D ). Compared with no treatment, all NAIs reduced the daily SIR of influenza A, with the extent of daily SIR reduction ranging from 49% (reduced from 2.87% to 1.47%) with oseltamivir to 75%
(reduced from 2.87% to 0.71%) with peramivir. The results of sensitivity analyses were similar (data not shown).
| Rate of household members with secondary infections
As with the daily SIR, the overall rate of household secondary infection varied depending on the NAI used by the index patient 
| Proportion of households with secondary infections
The proportion of households with at least one secondary infection also varied depending on the NAI used by the index patient 
| D ISCUSS I ON
In this large, prospective, observational study of data collected across six influenza seasons, the rate of influenza transmission within households varied depending on the NAI used to treat the Although several previous studies have compared the ability of NAIs to reduce household transmission, this is the first to compare all four NAIs available in Japan, the first to examine influenza types and subtypes, and the first to include data from more than one season.
Consistent with our study, two previous studies reported that influenza transmission was higher with oseltamivir than with zanamivir 9, 10 or laninamivir, 10 although a third study found no difference between oseltamivir and zanamivir. 6 All these studies focused on a single influenza season, and none characterized transmission by influenza type or subtype. Further, no previous study has included intravenous peramivir in the comparison, probably because it is prescribed to outpatients less often than other NAIs due to its route of administration. 5 The current study also indicates that peramivir generally shows a lower daily SIR and is similar to zanamivir in reducing household transmission of influenza A, the dominant influenza type in almost all seasons. In the other type and subtype analyses, the differences in daily SIR between NAIs were most apparent for influenza subtype A/H3 and influenza B, whereas the ability to reduce household transmission of influenza A/ H1pdm did not differ significantly. Apart from oseltamivir, we found no significant differences between the other NAIs in their ability to limit The differences between NAIs in the ability to reduce household influenza transmission may relate to differential effects on viral dynamics. NAI treatment reduces the duration of viral shedding, especially when administered within 48 hours after the onset of illness. 11, 20, 21 This reduction in viral shedding may lessen household transmission,
F I G U R E 4 Proportion of households with any secondary infection for influenza A (panel A) and B (panel B)
. Shown are unadjusted estimates and 95% confidence intervals (CI) when index patients were treated with peramivir, oseltamivir, zanamivir, or laninamivir, and unadjusted and adjusted odds ratios (OR) of pairwise comparisons between neuraminidase inhibitors particularly if given early. 9 Several studies have compared the ability of oseltamivir to reduce viral shedding with that of other NAIs. In contrast, the time to resolution of fever or symptoms did not vary with NAI treatment. 16 Other randomized trials have also reported that viral load is reduced more rapidly with peramivir than with oseltamivir, although the reported differences varied and were not always statistically significant. [25] [26] [27] Although our data do not allow us to directly link in previous studies were limited by the assumption that subsequent infections within a family were always transmitted from the primary infection or the models did not consider this aspect at all. 6, 7, [9] [10] [11] [12] [13] Although this study is limited by its observational, nonrandomized design, the results do reflect real-world clinical practice, albeit in a single clinic in a major Japanese city. There is potential for bias in the choice of NAI for specific patients, for example, for children vs adults or for patients who cannot use inhaled NAIs. However, such potential bias would have been minimized by adjusting for age in the analysis. There is also potential bias if patients with more severe symptoms, which may reflect a more transmissible infection, were more likely to visit the clinic, and to visit soon after the onset of symptoms, than patients with milder symptoms. However, body temperatures at first visit were only moderately elevated (approximately 38°C), suggesting that symptoms were generally not severe. As with all household transmission studies, asymptomatic household members (both primary and secondary infections) could not be identified for inclusion.
In addition, the relatively small number of patients with influenza A/H1pdm and influenza B may have limited our ability to detect a significant difference between NAIs for these strains of virus.
Further, we did not analyze serial intervals or adherence rates for NAIs requiring multiple doses, although patients were followed closely and were assumed to have completed the prescribed course. In practice, better adherence would be expected with single-dose NAIs such as peramivir than with multidose NAIs.
Finally, although our analysis of daily SIR adjusted for age, time from onset to start of treatment, and vaccine in the same season, other factors may have affected the results.
In conclusion, NAIs differ in their ability to reduce household transmission of influenza, with oseltamivir being generally less effective than other NAIs, particularly peramivir and zanamivir. Given the public health implications of limiting the spread of influenza infection, physicians should consider prescribing NAIs that are most effective at reducing household transmission and ensure that treatment is initiated early.
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